Special Issue "Vaccine Delivery"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (30 June 2015)
Prof. Vasso Apostolopoulos
1. College of Health and Biomedicine, Centre for Chronic Disease Prevention and Management, Victoria University, VIC 8001, Australia
2. VA Consulting Services, Melbourne, VIC 3000, Australia
Interests: vaccine delivery methods; immunotherapeutics; cancer; autoimmunity; immune cell stimulation
Over 1,000 years ago in China, contents of smallpox vesicles were injected into people who had not previously experienced smallpox. Fatalities were uncommon in the individuals inoculated with the smallpox vesicles, compared with victims of natural smallpox infection. More than 700 years later, Edward Jenner injected an 8 year old boy with cowpox and challenged him with smallpox, the boy was subsequently protected against smallpox. Hence the term “cross reactivity” was coined. Two hundred year later, smallpox vaccination became increasingly popular in the decade 1967-1977 and complete world-wide eradication was accomplished. Numerous methods of vaccination have been used, such as, attenuated bacteria, live virus’s, dead organisms and despite their success, a number of disasters in humans have resulted. Disasters were primarily due to improper lab manufacturing and handling and consequently these incidences led to improved procedures and the safety of vaccines, and led to regulatory measures to assure proper laboratory conditions. With attempts to control more complex diseases and the need to improve vaccine safety, stability, efficacy and cost, there is pressure for precisely defined vaccines.
Public awareness of health and safety issues vaccines must now meet higher standards of safety and biochemical characterization than they did in the past. Some of the vaccines developed in the past would not even meet the minimum standards required today. Hence, new improved precisely defined highly purified vaccines need to be developed. Advances in the fields of peptide synthesis, molecular biology, protein production, immunology, animal models etc are required for the development of new and improved vaccines, in an attempt to move from traditional live virus vaccines to the theoretical safer but ‘less immunogenic’ vaccines. In an attempt to improve the immunogenicity of the highly purified vaccines, a number of technologies and delivery methods have been utilized. This special issue will present, delivery methods used to improve immunogenicity of vaccines, and their in vitro and in vivo biological activities with the aim to go into human clinical trials.
Prof. Dr. Vasso Apostolopoulos
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. Papers will be published continuously (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are refereed through a peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed Open Access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 300 CHF (Swiss Francs). English correction and/or formatting fees of 250 CHF (Swiss Francs) will be charged in certain cases for those articles accepted for publication that require extensive additional formatting and/or English corrections.